Ibrutinib-Rituximab Combo Beats Chemoimmunotherapy for CLL
Progression-free, overall survival improved in the ibrutinib-rituximab group at three years.
Diagnosis & Disease Information
Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies
Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.
Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura
Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.
Rituximab Maintenance Prolongs PFS in Patients With CLL
New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
[Blood and Lymphatic Cancer: Targets and Therapy] This research examines the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of indolent B-cell malignancies.
Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL
For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.
ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma
Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma.
Targeting CD20 in chronic lymphocytic leukemia
[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.
Infusion times for rituximab
Other oncology nurses have mentioned to me that they infuse rituximab (Rituxan) over 90 minutes. Are there references for this?
FDA Update November/December 2012
Paclitaxel protein-bound particles for injectable suspension, 90-minute infusion of rituximab, omacetaxine mepesuccinate receive FDA approval
- Loading...
Loading...
Loading... 
Loading...